Palbociclib was believed to be an anti-tumor agent only in ER+ breast cancer in previous studies, our findings noted that both ER+ and ER− breast cancer had the potential to benefit from palbociclib treatment. This evidence concerns the gene ESR1 and breast carcinoma.